Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

NCT00145158 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

23

Enrollment

OTHER

Sponsor class

Stopped Availability of Investigational agent

Conditions

Malignant Melanoma

Interventions

BIOLOGICAL: 8 HLA-A2-restricted peptides and Montanide ISA51
BIOLOGICAL: 8 HLA-A2-restricted peptides and CpG 7909

Sponsor

Ludwig Institute for Cancer Research